Original Research Article
Year: 2014 | Month: February | Volume: 4 | Issue: 2 | Pages: 68-72
Incidence of Hypoglycemia and Other Side Effects in Patients of Type 2 Diabetes Mellitus Treated with Glimepiride versus Glibenclamide
Meenu Rani1, Shailesh Yadav2, Seema Choudhary3, Seema Sharma4, Surya Mani Pandey5
1Demonstrator, Deptt of Pharmacology BPS GMC for women Khanpur kalan.
2Professor, Deptt of Pharmacology MMIMSR. Mullana, Ambala.
3Professor, Deptt of Community Medicine, MAMC. Agroha, Hisar.
4Assistant Prof. Deptt of Community Medicine, MAMC. Agroha, Hisar.
5Assistant Prof., MAMC.Agroha, Hisar.
Corresponding Author: Meenu Rani
ABSTRACT
Background: Sulfonylureas were among the first oral antihyperglycemic agents developed, but patients on a sulfonylureas experience hypoglycemia. Severe hypoglycemia was a potentially life-threatening condition. Objective: The aim of the study was to compare the frequency of hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Material &Methods: Total 50 patients were included in the study. These patients were divided in group I & II. Group I (n=25): Patients were given Tab. Glibenclamide. Group II (n=25): Patients were given Tab. Glimepiride for 24 weeks. Results: Patients with glibenclamide experienced hypoglycemia (12%) and weight gain (4%) as the main adverse effects while patients with glimepiride had no such adverse effects. Conclusion: In people with type 2 diabetes, glimepiride was associated with fewer episodes of hypoglycemia than glibenclamide.
Key words: Type 2 diabetes mellitus, glimepiride, glibenclamide, hypoglycemia, sulfonylureas.